GET DAILY SIGNALSWhy Is Pulmonx Corporation (LUNG) Stock Up +10.32% Today?
Key Takeaways
- Shares of LUNG rose about 10.3% to roughly $2.78, extending a powerful two-session, earnings-driven rally.
- Primary catalyst: a third-quarter earnings beat that showed a return to year-over-year revenue growth and sharply narrower losses.
- Secondary driver: bullish analyst actions, including a Stifel price-target increase to $4.00 and a reiterated Canaccord Buy rating.
- Broader context: the move tracked strength across small-cap medtech and healthcare names, with trading volume running well above average.
- What traders are watching next: fourth-quarter commercial execution, a China shipment restart, and upcoming investor conferences.
- For additional detail on this stock, explore our Price Targets, Earnings, and Forecast pages.
- To see how AI-powered strategies are trading this and thousands of other tickers, visit Trending AI Robots.
Opening Summary
Pulmonx Corporation (LUNG), a Redwood City, California-based medical technology company and global leader in minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease (COPD), extended its post-earnings advance on Thursday. The stock climbed roughly 10.3% to around $2.78, up from a prior session close of $2.52, continuing a surge that began after the company reported better-than-expected third-quarter results earlier in the week. Markets attributed the strength to a beat-and-raise style earnings report, a return to top-line growth, and a wave of bullish analyst commentary.
Earnings Results and Return to Growth
The dominant catalyst behind the rally is Pulmonx's third-quarter 2026 report. The company posted revenue of $22.8 million, up 6% from $21.5 million a year earlier and ahead of consensus estimates of roughly $21.9 million. U.S. revenue rose 7% to $14.9 million, while international revenue increased 5% to $7.9 million — growing about 9% excluding China. The quarter marked the company's first return to global year-over-year revenue growth since its current leadership team rejoined the business.
Profitability metrics also improved meaningfully. The net loss narrowed 40% to $8.4 million, or $0.19 per share, compared with a $14.0 million loss, or $0.34 per share, in the prior-year period — beating the $0.26 loss-per-share consensus. Adjusted EBITDA loss fell nearly 60% to $3.5 million, gross margin improved to 76% from 75%, and operating expenses declined 18% to $24.9 million. Management reiterated full-year 2026 revenue guidance of $90 million to $92 million and raised its full-year gross margin outlook to approximately 77%.
Analyst Upgrades Fuel the Momentum
The fundamental beat was amplified by a series of constructive research notes. Stifel raised its price target on LUNG to $4.00 from $2.50 while maintaining a Buy rating, and Canaccord Genuity reiterated its Buy stance with a higher price objective. These endorsements reinforced the view that Pulmonx's rebuilt U.S. sales organization and refocused commercial strategy are beginning to gain traction, giving investors additional conviction to chase the stock higher across multiple sessions.
Market Context and Trading Activity
Trading volume was exceptionally heavy, reflecting outsized investor interest following the earnings release. The stock also broke decisively above its 50-day moving average, a technical signal that often attracts momentum-oriented and quantitative buyers. The move aligned with broad strength in small-cap medtech and healthcare names, even as the company's own catalyst — rather than a market-wide tailwind — remained the primary driver. The advance pushed the shares toward the upper portion of their 52-week range, underscoring the magnitude of the two-day repricing.
What Comes Next for LUNG
Investors will now focus on whether Pulmonx can sustain its return to growth into the fourth quarter. Key watch items include continued productivity gains from the rebuilt U.S. sales team, the resumption of China shipments to its distributor expected by early next year, and any incremental updates from upcoming investor conferences. Risks remain: the company still operates at a net loss, cash burn is ongoing, and AeriSeal revenue is not expected to contribute materially until 2028. Sustaining the momentum will depend on consistent execution against the reiterated full-year outlook.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots covering thousands of tickers. While Tickeron offers hundreds of bots, only the strongest performers under current market conditions are featured in this section, with strategies varying by approach, timeframe, performance metrics, and traded symbols. Explore the page to see how these automated strategies are navigating today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LUNG in upward trend: price rose above 50-day moving average on October 28, 2026
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +29.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.761) is normal, around the industry mean (3.824). P/E Ratio (-2.191) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement